在基因编辑方面，公司推出了包括CAS9、CAS12a等CAS系列蛋白，主要用于定点基因编辑等，以提供高编辑效率。 (记者 蔡鼎) 免责声明：本文内容与数据 ...

Optimized methods for the synthesis of circular RNA in vitro and in cells, and a complementary Cas9 de-immunization ... specific enhancement strategy for Cas12a via iterative crRNA design.

At this time, the core can perform genome editing with S.p. Cas9 or A.s. Cas12a/Cpf1. The targeting will be done in embryos using microinjection to introduce the CRISPR reagents. The investigator will ...

To access the live webcasts of Eitas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for ...

About Editas Medicine As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a ...